You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IDH

Showing 1 - 25 of 392
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult Trial (NEO212 Oral Capsule, Ipilimumab,

Not yet recruiting
  • Diffuse Astrocytoma, IDH-Mutant
  • +20 more
  • NEO212 Oral Capsule
  • +8 more
  • (no location specified)
Sep 18, 2023

Glioblastoma Trial in Rotterdam (Extended MRI)

Recruiting
  • Glioblastoma
  • Extended MRI
  • Rotterdam, Zuid-Holland, Netherlands
    Erasmus Medical Center
Jul 24, 2023

Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma Trial in Padova (Regorafenib, Temozolomide)

Recruiting
  • Glioblastoma, IDH-wildtype
  • MGMT-Methylated Glioblastoma
  • Padova, Italy
    Istituto Oncologico Veneto IRCCS
Oct 18, 2023

Cholangiocarcinoma With IDH1 Mutation, Solid Tumors With IDH1 Mutation Trial in Beijing (AB-218 capsule)

Not yet recruiting
  • Cholangiocarcinoma With IDH1 Mutation
  • Solid Tumors With IDH1 Mutation
  • AB-218 capsule
  • Beijing, Beijing, China
    Peking Union Medical College Hospital, Chinese Academy of Medica
Apr 2, 2023

Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma Trial in Boston (Niraparib, Resection/Treatment with Niraparib)

Recruiting
  • Low-grade Glioma
  • +4 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 19, 2022

Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma Trial in Houston (other,

Recruiting
  • Anaplastic Astrocytoma, IDH-Wildtype
  • +8 more
  • Quality-of-Life Assessment
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 8, 2022

Recurrent IDH1/2 Mutated Glioma Trial in Paris (Azacitidine)

Recruiting
  • Recurrent IDH1/2 Mutated Glioma
  • Paris, France
    Pitie Salpetriere Hospital
Aug 29, 2022

Brain Tumor, Cancer Trial run by the National Cancer Institute (NCI) (Zotiraciclib)

Not yet recruiting
  • Brain Tumor
  • Cancer
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Adult Gliomas, Mixed Trial in San Francisco (Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG), Magnetic Resonance Image

Recruiting
  • Adult Gliomas, Mixed
  • Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)
  • Magnetic Resonance Image (MRI)
  • San Francisco, California
    University of California, San Francisco
May 9, 2023

Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer Trial in Edmonton, Toronto (Enasidenib, Venetoclax)

Active, not recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Edmonton, Alberta, Canada
  • +1 more
Jan 31, 2023

IDH1-mutant Cholangiocarcinoma Trial (Ivosidenib, Recommended Combination Dose (RCD) of ivosidenib, Nivolumab)

Not yet recruiting
  • IDH1-mutant Cholangiocarcinoma
  • (no location specified)
Jun 29, 2023

Correlation Between SPECT/CT and IDH Mutation in Brain Glioma

Not yet recruiting
  • Brain Glioma
    • (no location specified)
    Oct 23, 2022

    Glioblastoma Trial in Beijing (PLB1001, Temozolomide, Cisplatin combined with Etoposide)

    Active, not recruiting
    • Glioblastoma
    • Beijing, Beijing, China
      Beijing Tiantan Hospital,Capital Medical University
    Oct 27, 2023

    Acute Myeloid Leukemia Trial in Columbus (Azacitidine, Biopsy, Enasidenib)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Jun 30, 2022

    Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic Trial (Ivosidenib)

    Not yet recruiting
    • Cholangiocarcinoma Non-resectable
    • Cholangiocarcinoma Metastatic
    • (no location specified)
    Oct 10, 2023

    Single Photon Emission Computed Tomography/Computed Tomography

    Not yet recruiting
    • Brain Glioma
    • SPECT with pentavalent 99mTc DMSA
    • (no location specified)
    Oct 23, 2022

    Glioma, IDH Mutation, Astrocytoma Trial in Philadelphia (Retifanlimab, All-trans retinoic acid)

    Not yet recruiting
    • Glioma
    • +3 more
    • Philadelphia, Pennsylvania
      University of Pennsylvania
    Jul 22, 2022

    Glioma, Malignant, Computer-Assisted Trial in Shanghai (Validation of IDH1 mutations from the radiomics model)

    Active, not recruiting
    • Glioma, Malignant
    • Computer-Assisted
    • Validation of IDH1 mutations from the radiomics model
    • Shanghai, Shanghai, China
      Huashan Hospital, Fudan University
    Jul 23, 2023

    Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,

    Not yet recruiting
    • Recurrent Glioblastoma, IDH-Wildtype
    • +2 more
    • Biospecimen Collection
    • +2 more
    • (no location specified)
    May 13, 2023

    Glioma, Gliomas, High Grade Glioma Trial run by the National Cancer Institute (NCI) (3T MRI scanner)

    Recruiting
    • Glioma
    • +4 more
    • 3T MRI scanner
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 2, 2023

    Astrocytoma, Oligodendroglioma, Adult, Glioma, Malignant Trial in Saint Louis (temporally-modulated pulsed radiotherapy (TMPRT))

    Recruiting
    • Astrocytoma
    • +2 more
    • temporally-modulated pulsed radiotherapy (TMPRT)
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jan 19, 2023

    Astrocytoma Trial (Vorasidenib, Pembrolizumab)

    Not yet recruiting
    • Astrocytoma
    • (no location specified)
    Aug 1, 2022

    Acute Myeloid Leukemia (AML) Trial in United States (Gilteritinib, Ivosidenib, Enasidenib)

    Not yet recruiting
    • Acute Myeloid Leukemia (AML)
    • Basking Ridge, New Jersey
    • +6 more
    Mar 3, 2023

    IDH-mutant and IDH-wildtype Glioma Patients After

    Recruiting
    • Glioma
    • RS-fMRI
    • Saint Louis, Missouri
      Washington University School of Medicine
    Mar 8, 2022

    Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme Trial in Cleveland (Eflornithine (Dose Level 1), Eflornithine

    Recruiting
    • Glioblastoma, IDH-wildtype
    • +4 more
    • Eflornithine (Dose Level 1)
    • +3 more
    • Cleveland, Ohio
      The Cleveland Clinic
    May 19, 2023